Vivos Therapeutics, Inc. is a medical technology manufacturer focused on the development and commercialization of solutions for patients with sleep disordered breathing (SDB), including obstructive sleep apnea (OSA). Registered with the FDA as a Specification Developer, we develop and market a number of FDA cleared and registered specially-designed, customized and preformed oral appliances.

Our technology represents the first non-surgical, non-invasive and cost-effective solution for the hundreds of millions of people globally who suffer from OSA. The Vivos System is a proprietary therapeutic protocol of functional and oral appliance therapy that we believe is gently remodeling and enhancing the size, shape, and function of the airway by mimicking biological processes.

The Vivos System has been shown to significantly lower Apnea Hypopnea Index (AHI) scores and improve other conditions associated with OSA.

Vivos clinicians can be found in almost every major city in the U.S. and in many countries throughout the world. Our oral appliances have shown to be effective in over 8,000 patients successfully treated worldwide by approximately 1,000 trained dentists.

The Vivos System can reduce or possibly eliminate the need for surgery or lifetime CPAP or mandibular advancement oral therapy.

The Vivos System is affordable and treatment applicable and effective in people of all ages and most major commercial insurance payers reimburse for Vivos System treatment

According to a 2019 publicly available analysis from researchers at the University of California, San Diego, an estimated 81 million adults in the North and South America suffer from moderate to severe OSA. The United States has the highest amount of these patients with approximately 54 million adults affected, according to such analysis.

In line with our growth strategy, our company has established FDA approved and registered manufacturing facilities in the US, Canada and Asia.

 

Download Investor Kit

Compare the Vivos® System to other treatment options.

Non-Surgical Options

Surgical Options

Treatment Protocol

CPAP

Oral Appliance

Therapy

Uvulopalatopharyn

Goplasty (UPPP)

Maxillomandibular

Advancement Surgery

Targets the Root Cause

YES

NO

NO

NO

YES

YES

Time to Relieve Symptoms

Potentially Immediate

Potentially Immediate

Potentially Immediate

Potentially Immediate

Potentially Immediate

Potentially Immediate

Overall Efficacy

High

Patient Compliance Dependent

High

Patient Compliance Dependent

High

Patient Compliance Dependent

Good

Requires proper diagnosis and

patient selection

Low - Medium

High

Pain

Very Minor or None

Very Minor or None

Very Minor or None

In Some Cases

During Recovery

During Recovery

Potential Negative
Side Effects

Minor Cosmetic

Moderate

Moderate

Major

Major

Major

Treatment Time

9 -18 Months

Lifetime

Lifetime

Lifetime

Surgery + Recovery

Surgery + Recovery

Duration of Benefits

Many Years / Lifetime

Only When Device is Used

Only When Device is Used

Only When Device is Used

Limited + Fade with Time

Many Years / Lifetime

Portability

Yes

Limited

Yes

N/A

N/A

N/A

Possible Cosmetic Benefit

Yes

No

No

N/A

N/A

Yes

Impact on TMJ

May Resolve

None Known

May Cause or Exacerbate

None Known

None Known

None Known

Download Investor Kit

Treatment options to relieve symptoms.

There are a number of effective treatment options to relieve the visible symptoms and manage obstructive sleep apnea.

CPAP

Mandibular

Advancement

Surgical

Intervention

Surgical

Implants

Breathe New Life   (602) 903-0095

Download Investment Offering

Vivos Therapeutics Investment Offering

For Institutional Buyers and Accredited Investors Only

Kevin Harrington of Shark Tank

Do you know someone who suffers from obstructive sleep apnea?

While these treatments can be effective at managing the symptoms of OSA,

they do not correct the underlying problem.

Pneumopedics®

Pneumopedics® is the natural process induced by Vivos biomimetic technology by which the airway tissues are remodeled resulting in enhanced capacity.

 

The Vivos System® multidisciplinary treatment protocol involves collaboration between physicians, specially-trained dentists who have completed advanced training in craniofacial sleep medicine, and other ancillary healthcare providers.

 

 

 

 

Stem Cells, Sleep, and Your Practice with Dr. Dave Singh, DMD Phd DDSc

Dental Success Institute - The Dentalpreneur Podcast

Listen

Dr. Dave Singh
DMD PhD DDSc

Founder

The Global Summits Institute recently named Dr. Singh one of the Top 100 Doctors in Dentistry

Read More

Vivos® Pneumopedic® Oral Appliance Therapy

The Vivos DNA appliance shown is registered as a Class I oral appliance for palatal expansion.

The mRNA appliance, a version of the DNA appliance is FDA cleared as a Class II appliance.

 

The mRNA is cleared to treat mild to moderate sleep apnea, snoring and sleep disorded breathing in adults.

Hope for a lasting resolution by targeting the root cause.

Biomimetic Appliance In Situ

Transduction Signaling

Underdeveloped Craniofacial Anatomy

Swollen Tonsils & Adenoids

Mandibular Retrognathia

Nasal Obstruction

Nasal Obstruction

Obstructed Airway

Maxillary Hypoplasia

The leading cause of obstructive sleep apnea is a deficiency in the development of craniofacial anatomy.

 

Physicians see patients everyday who are suffering from the affects of Obstructive Sleep Apnea. Very few tolerable treatment options exist.

 

What if there was another way?

Dr. Sam DeMaria, MD
Anesthesiologist

Dr. Yuri Khelemsky, MD
Anesthesiologist &

Chronic Pain Specialist

Dr. Seth Heckman, MD
Obstetrician & Gynecologist

Dr. Fred Lin, MD
Otolaryngologist &

Sleep Surgery Specialist

Dr. Cecilia Wu
Forensic & Cardiovascular
Pathologist

Dr. Manisha Witmans, MD
Pediatric Pulmonology &

Sleep Medicine Specialist

A new paradigm in sleep medicine.

Obstructive Sleep Apnea

A Serious Concern for Every Doctor

Download Investor Kit

Sleep Disordered Breathing Comorbidities

"Sleep disordered breathing including mild-to-moderate obstructive sleep apnea impacts every system in the body."

Dr. Manisha Witmans, MD
Pediatric Pulmonology &

Sleep Medicine Specialist

Continuous Positive Airway Pressure - The Standard of Care

Non-Compliance - The Leading Cause of Poor Treatment Outcomes

“Despite the efficacy of CPAP in reversing sleep apnea, of those studies using the cut point of at least 4 hours per night to define adherence, 29% to 83% of patients were nonadherent.”

 

ATS Journals – American Thoracic Society
November 30, 2007

{

 

 

The Leading Cause of OSA is Craniofacial Anatomical Deficiencies

Nasal Obstruction

 

Mandibular Retrognathia

 

Maxillary Hypoplasia

 

Obstructed Airway

 

Target and treat the underlying condition.

Arch Otolaryngol Head Neck Surg.

2011; 137(10):990-996

{

 

 

ADD | ADHD

Allergies

Snoring

Cardiovascular Disease

Obesity

Enuresis

Chronic Fatigue

Chronic Fatigue

Diabetes

Depression + Anxiety

Grinding Teeth

Asthma

Hypertension

Cancer

Chronic Pain

Chronic Pain

Fibromyalgia

Craniofacial Anatomy

“In 98% of patients with OSA, the condition is due to abnormal anatomical features of the soft tissues and/or the structures of the maxillomandibular skeleton that cause a disproportionate anatomy of the airway.”

 

 

Pneumopedics® - A Therapeutic Breakthrough

Pneumopedics® targets the root cause in 98% of cases of Obstructive Sleep Apnea

 

Download Investor Kit

A treatment protocol that targets the underlying cause of sleep apnea.

The Vivos System® works to treat the root cause of OSA by non-surgically remodeling and repositioning the hard and soft tissues that comprise the human airway.

 

The Vivos System® treatment is typically less than $10,000 and is covered by most major health plans.

 

 

Diagnosis

Airway Evaluation & Planning

Biomimetic Therapy

A therapeutic protocol offering hope for a lasting resolution.

3D Axial Springs for
Transduction Signaling

Three-Way Development Screw

Pharyngeal Extension

Transverse Screw

Labial Bow

A potentially serious medical problem with a solution in the dental office.

Vivos DNA Appliance®

Hard and soft tissues of the craniofacial complex can be non-surgically remodeled and enhanced using the proprietary Vivos System® devices and clinical protocols.

 

 

 

 

The Vivos DNA appliance shown is registered as a Class I oral appliance for palatal expansion.

The mRNA appliance, a version of the DNA appliance is FDA cleared as a Class II appliance.

 

The mRNA is cleared to treat mild to moderate sleep apnea, snoring and sleep disorded breathing in adults.

17cm3

28cm3

Craniofacial developmental deficiencies are the leading cause of the obstruction in obstructive sleep apnea.

Singh and Cress, Dent Today 2013

 

Biomimetic Oral Appliance

Upper Airway Remodeling

An Obstructed Airway

Download Investor Kit

Vivos® In The News

Benco Dental announces strategic alliance with Vivos Therapeutics, Inc.

Vivos and Benco Dental will collaborate to help make all dentists in the United States aware of the company's unique apnea treatment.

Read The Benco Press Release

Vivos® Strategic Relationships

Vivos® For Patients

Vivos® For Healthcare Professionals

Vivos® For Investors

At Vivos, we strive to provide useful information to help you when discussing your health concerns with your doctor. Our goal is to strengthen your relationship with your healthcare team to ensure proper diagnosis and treatment.

At Vivos, we support healthcare professionals around the world who are focused on treating the root cause of sleep disordered breathing including mild-to-moderate obstructive sleep apnea resulting from craniofacial deficiencies.

Our business is helping to address challenges throughout the world. We are helping to reduce the overall cost of healthcare by targeting a prevalent condition which contributes to many of the most expensive healthcare problems.

The Company has engaged Weild & Co., a FINRA member broker-dealer, as lead placement agent for the Offering. See additional information provided in the Investor Kit.

 

Company Contact: Ed Loew 602-903-0095  or ed@vivoslife.com

©2018-2020 Vivos® Therapeutics, Inc.  |  ALL RIGHTS RESERVED        The Company has engaged Weild & Co., a FINRA member broker-dealer, as lead placement agent for the Offering. See additional information provided in the Investor Kit.

All content found on this website, including text, images, audio, or other formats were created for informational purposes only. The content of this website is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. Individual results may vary. Nothing contained in this website infers or creates a warranty, promise, or guarantee of any kind with respect to the clinical outcome or result from treatment using the Vivos technology. The use of the Vivos technologies by any patient must always occur under the direction and supervision of a qualified, trained, and licensed dentist, physician or other qualified health provider, working in close collaboration with qualified medical personnel.

THE INVESTMENT DESCRIBED IN THIS WEBSITE IS OPEN TO "ACCREDITED INVESTORS" ONLY, THROUGH AN OFFERING MADE IN ACCORDANCE WITH REGULATION D, RULE 506(c) OF THE SECURITIES ACT OF 1933, AS AMENDED.

 

THIS INVESTMENT IS SPECULATIVE AND INVOLVES A HIGH DEGREE OF RISK, INCLUDING THE POTENTIAL LOSS OF AN ENTIRE INVESTMENT.  IT IS SUITABLE ONLY FOR SOPHISTICATED, “ACCREDITED” INVESTORS ONLY WHO HAVE EXPERIENCE IN INVESTMENTS IN DEVELOPING MEDICAL TECHNOLOGY COMPANIES.

 

FURTHERMORE, POTENTIAL INVESTORS MUST UNDERSTAND THAT THIS INVESTMENT COULD BE ILLIQUID FOR AN INDEFINITE PERIOD OF TIME.  NO PUBLIC MARKET CURRENTLY EXISTS FOR THE SECURITIES OFFERRED, AND IF A PUBLIC MARKET DEVELOPS FOLLOWING THE OFFERING, IT MAY NOT BE ACTIVE OR CONTINUE.

 

THIS EMAIL AND WEBSITE CONTAIN A NUMBER OF OFFERING DOCUMENTS RELATED TO THE TRANSACTION.  PLEASE CAREFULLY READ EACH, PAYING PARTICULAR ATTENTION TO THE INVESTMENT RISKS IDENTIFIED IN THE COMPANY’S CONFIDENTIAL EXECUTIVE SUMMARY & &ISKS DISCLOSURE BOOKLET PRIOR TO MAKING ANY INVESTMENT DECISIONS.

 

 

 

You may not rely on any information concerning an investment in the Company other than the offering materials furnished by the Company upon request. Kevin Harrington’s endorsement is not intended to supplement or modify such offering materials, and you should carefully review such offering materials and consult with your own financial, accounting, and legal professionals prior to making any investment decision with respect to the Company.

 

Mr. Harrington is an investor in the Company; however, Mr. Harrington has been compensated for providing the foregoing endorsement. Additionally, Mr. Harrington provides certain consulting services to the Company for compensation. Mr. Harrington’s endorsement does not mean that an investment in the Company is legitimate or appropriate for all investors. You should not make an investment decision based solely on Mr. Harrington’s endorsement, or other information you receive through social media, investment newsletters, online advertisements, email, investment research websites, internet chat rooms, direct mail, newspapers, magazines, television, or radio. You must make your own independent decision that an investment in the Company is suitable and appropriate for you, taking into account all relevant factors concerning your complete financial profile and investment experience. Please visit the website of the SEC’s Office of Investor Education and Advocacy at www.investor.gov for general information about investing.

 

The Company is not affiliated in any way with Finnmax, LLC, One Three Television LLC, CNBC LLC, NBC Universal News Group, Sony Pictures Television, Mark Burnett Productions, the Shark Tank television show, the cast of the Shark Tank television show, American Broadcasting Company, or the Disney Companies.